MedTrace Logo

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

NCT04620603 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-05-05

No results posted yet for this study

Summary

This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.

Conditions

  • Cutaneous Malignant Melanoma
  • Renal Cell Cancer
  • Urothelial Cancer of Renal Pelvis

Interventions

RADIATION

Low Dose Rate Brachytherapy (LDR)

LDR on treatment day 1

DRUG

Standard-of-Care Immunotherapy

Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.

Sponsors & Collaborators

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Jay Ciezki, MD · Cleveland Clinic, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2024-03-20
Completion
2026-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620603 on ClinicalTrials.gov